Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CORT 
Corcept Therapeutics Incorporated (CORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: CORT (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $135.25
1 Year Target Price $135.25
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.3% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.82B USD | Price to earnings Ratio 66.22 | 1Y Target Price 135.25 |
Price to earnings Ratio 66.22 | 1Y Target Price 135.25 | ||
Volume (30-day avg) 4 | Beta 0.46 | 52 Weeks Range 49.00 - 117.33 | Updated Date 11/3/2025 |
52 Weeks Range 49.00 - 117.33 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.12 |
Earnings Date
Report Date 2025-10-29 | When - | Estimate 0.1344 | Actual - |
Profitability
Profit Margin 18.67% | Operating Margin (TTM) 13.72% |
Management Effectiveness
Return on Assets (TTM) 8.36% | Return on Equity (TTM) 21.7% |
Valuation
Trailing PE 66.22 | Forward PE 26.32 | Enterprise Value 8671554394 | Price to Sales(TTM) 10.91 |
Enterprise Value 8671554394 | Price to Sales(TTM) 10.91 | ||
Enterprise Value to Revenue 12.11 | Enterprise Value to EBITDA 83.51 | Shares Outstanding 105371729 | Shares Floating 86954858 |
Shares Outstanding 105371729 | Shares Floating 86954858 | ||
Percent Insiders 11.55 | Percent Institutions 76.59 |
Upturn AI SWOT
Corcept Therapeutics Incorporated
Company Overview
History and Background
Corcept Therapeutics Incorporated was founded in 1998. It focuses on the discovery, development, and commercialization of medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol. A significant milestone was the FDA approval of Korlym in 2012. The company has evolved from a research-focused entity to a commercial-stage pharmaceutical company.
Core Business Areas
- Endocrine Oncology: Development and commercialization of drugs that modulate cortisol to treat cancer, particularly adrenal cancer and castration-resistant prostate cancer.
- Metabolic Diseases: Researching and developing treatments for metabolic diseases, including hypercortisolism (Cushing's syndrome).
Leadership and Structure
Joseph K. Belanoff, M.D., serves as the Chief Executive Officer. The company has a traditional hierarchical structure with departments focused on research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Korlym (mifepristone): Korlym is used to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Competitors are Signifor and Isturisa. Market share information is proprietary but Korlym is the primary revenue driver for the company.
- Relacorilant: Relacorilant is a selective cortisol modulator currently in clinical development for Cushing's syndrome and castration-resistant prostate cancer. If approved, it will compete with Korlym, Signifor, and Isturisa. As it is still not approved, its market share is currently 0, but projected revenues are strong with a possible approval in the future.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with constant innovation and regulatory scrutiny. The market for treatments targeting cortisol modulation is growing, driven by unmet medical needs.
Positioning
Corcept is a leader in cortisol modulation therapies, particularly for Cushing's syndrome. Its competitive advantages include its established expertise in this area and its proprietary portfolio of cortisol modulators.
Total Addressable Market (TAM)
The total addressable market for Cushing's syndrome treatment is estimated to be in the hundreds of millions of dollars annually. The castration-resistant prostate cancer market is significantly larger, potentially billions. Corcept is positioned to capture a significant share of these markets with its pipeline.
Upturn SWOT Analysis
Strengths
- Established expertise in cortisol modulation
- Proprietary portfolio of cortisol modulators
- FDA-approved product (Korlym)
- Strong financial position
Weaknesses
- Reliance on a single approved product (Korlym)
- Patent litigation risks
- Small market size for Cushing's syndrome
- High R&D costs
Opportunities
- Expansion into new indications (e.g., prostate cancer)
- Successful development and commercialization of relacorilant
- Partnerships and collaborations
- Geographic expansion
Threats
- Competition from other pharmaceutical companies
- Patent challenges
- Regulatory hurdles
- Generic entry for Korlym
- Clinical trial failures
Competitors and Market Share
Key Competitors
- NOVN
- PFE
- MRK
Competitive Landscape
Corcept's competitive advantage lies in its expertise in cortisol modulation. However, it faces competition from larger pharmaceutical companies with broader portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Corcept has experienced revenue growth driven by sales of Korlym. However, growth has been impacted by patent litigation and competition.
Future Projections: Analysts project future revenue growth driven by relacorilant, if approved, and potential expansion into new indications. Growth estimates vary widely depending on clinical trial outcomes and regulatory decisions.
Recent Initiatives: Corcept is focusing on the development and commercialization of relacorilant, expanding clinical trials into new indications, and defending its intellectual property.
Summary
Corcept Therapeutics is a pharmaceutical company specializing in cortisol modulation. Its financial health is good, and its flagship product, Korlym, continues to be its primary revenue source. The company is facing patent litigation, which represents a challenge. Its future growth hinges on the successful development of relacorilant and its ability to broaden its product pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Corcept Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise. Future performance is subject to various risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corcept Therapeutics Incorporated
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2004-04-14 | Co-Founder, President, CEO & Director Dr. Joseph K. Belanoff M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 500 | Website https://www.corcept.com |
Full time employees 500 | Website https://www.corcept.com | ||
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.